LENSAR Inc
NASDAQ:LNSR

Watchlist Manager
LENSAR Inc Logo
LENSAR Inc
NASDAQ:LNSR
Watchlist
Price: 8.665 USD -0.29%
Market Cap: 100.6m USD
Have any thoughts about
LENSAR Inc?
Write Note

LENSAR Inc
Note Receivable

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

LENSAR Inc
Note Receivable Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Note Receivable CAGR 3Y CAGR 5Y CAGR 10Y
LENSAR Inc
NASDAQ:LNSR
Note Receivable
$1.3m
CAGR 3-Years
42%
CAGR 5-Years
11%
CAGR 10-Years
N/A
Becton Dickinson and Co
NYSE:BDX
Note Receivable
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Boston Scientific Corp
NYSE:BSX
Note Receivable
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Stryker Corp
NYSE:SYK
Note Receivable
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbott Laboratories
NYSE:ABT
Note Receivable
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Intuitive Surgical Inc
NASDAQ:ISRG
Note Receivable
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

LENSAR Inc
Glance View

Market Cap
100.6m USD
Industry
Health Care

LENSAR, Inc. engages in the development of femtosecond laser technology for refractive cataract surgery. The company is headquartered in Orlando, Florida and currently employs 110 full-time employees. The company went IPO on 2020-09-21. The firm is focused on designing, developing, and marketing femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. The company has developed the LENSAR Laser System to provide an alternative laser cataract treatment tool that allows the surgeon to better address astigmatism and improve visual outcomes. Its product portfolio consists of the LENSAR Laser System with Streamline IV and IntelliAxis and its associated consumable components. The company is also developing an integrated cataract treatment system, ALLY, which is designed to combine its existing femtosecond laser technology with phacoemulsification system into a single unit and allow surgeons to perform each of the critical steps in a cataract procedure in a single operating room using this device.

LNSR Intrinsic Value
6.687 USD
Overvaluation 23%
Intrinsic Value
Price

See Also

What is LENSAR Inc's Note Receivable?
Note Receivable
1.3m USD

Based on the financial report for Dec 31, 2023, LENSAR Inc's Note Receivable amounts to 1.3m USD.

What is LENSAR Inc's Note Receivable growth rate?
Note Receivable CAGR 5Y
11%

Over the last year, the Note Receivable growth was 191%. The average annual Note Receivable growth rates for LENSAR Inc have been 42% over the past three years , 11% over the past five years .

Back to Top